Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 8Sarcoma 2

Conditions

Osteosarcoma 2Neuroblastoma 2

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × dinutuximab × Sarcoma × Clear all
NCT04751383 2026-01-21

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled 12 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT05400603 2025-12-26

Aflac-NBL-2002

Emory University

Phase 1 Recruiting
24 enrolled
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡